RALLYBIO CORPORATION Increase (Decrease) in Contract with Customer, Liability
RALLYBIO CORPORATION (RLYB) reported Increase (Decrease) in Contract with Customer, Liability of -$212.00 thousand for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-26
- RALLYBIO CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $0.00.
- RALLYBIO CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$212.00K.
- RALLYBIO CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$212.00K.
- RALLYBIO CORPORATION increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$212.00K.
- RALLYBIO CORPORATION increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | -$212.00K S-4/A · filed 2026-08-26 | -$424.00K derived: sum of 3 quarters · filed 2026-08-26 | -$636.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | -$212.00K S-4 · filed 2026-07-15 | -$424.00K derived: sum of 2 quarters · filed 2026-08-26 | -$636.00K derived: sum of 3 quarters · filed 2026-08-26 | -$848.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | -$212.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$424.00K derived: sum of 2 quarters · filed 2026-08-26 | -$636.00K derived: sum of 3 quarters · filed 2026-08-26 | -$848.00K S-4/A · filed 2026-08-26 |
| 2025-09-30 | -$212.00K derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-06 | -$424.00K derived: sum of 2 quarters · filed 2026-08-26 | -$636.00K 10-Q · filed 2025-11-06 | -$673.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | -$212.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | -$424.00K S-4/A · filed 2026-08-26 | -$461.00K derived: sum of 3 quarters · filed 2026-08-26 | -$761.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | -$212.00K S-4 · filed 2026-07-15 | -$249.00K derived: sum of 2 quarters · filed 2026-08-26 | -$549.00K derived: sum of 3 quarters · filed 2026-08-26 | $848.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | -$37.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$337.00K derived: sum of 2 quarters · filed 2026-08-26 | $1.06M derived: sum of 3 quarters · filed 2026-08-26 | $1.06M S-4/A · filed 2026-08-26 |
| 2024-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.10M derived: sum of 2 quarters · filed 2025-11-06 | $1.10M 10-Q · filed 2025-11-06 | $1.10M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.40M 10-Q · filed 2025-08-07 | $1.40M derived: sum of 3 quarters · filed 2025-08-07 | $1.40M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | $0.00 derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |